Prima Biomed +30% as clinical trial approved in multiple jurisdictions

|By:, SA News Editor

Prima Biomed (PBMD +29.9%) says multiple jurisdictions have approved its amended CAN-004 protocol including regulators in Latvia, Lithuania, Bulgaria, Ukraine and Belarus.

As previously announced, the CAN-004 trial was approved by the Belgian regulators in January.

PBMD says the CAN-004 amendment also has been approved by ethics committees and institutional review boards in the U.S., Australia, Belgium, Bulgaria, Latvia and Lithuania.